Our pipeline includes life cycle management initiatives for approved products mentioned above, as well as development compounds.

Our focus is on developing novel approaches to treating GERD beyond acid suppression.

During 2007, the Reflux Inhibitor AZD3355, which inhibits transient lower esophageal sphincter relaxations (TLESRs), was tested in patients with GERD and showed positive effects in a phase IIa study. The clinical development of AZD3355 in phase II is progressing.